Experts call out the need for affordable breast cancer treatment during the launch of trastuzumab biosimilar in the Philippines

In response to the prevailing threat of breast cancer in the Philippines, Pfizer has introduced a trastuzumab biosimilar to enable more Filipinos to have access to a more affordable treatment for HER2 positive breast cancer.

Announced during a recently held Oncology Summit organized by Pfizer and held at Grand Hyatt Manila, Taguig Philippines that was attended by leading healthcare practitioners and Oncology experts, Pfizer’s biosimilar Trastuzumab received the approval of the PhilippinesFood and Drug Administration (FDA) in March 2022 to bring this innovative treatment option to the Filipino patients. Trastuzumab refers to a monoclonal antibody that is used to treat specifictypes of HER2 positive breast cancers and stomach cancers.